"Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration -NO Jaume Sastre-Garriga
The study of the neurodegenerative component came to the forefront of multiple sclerosis research 20 years ago. 1 In the following years, MRI-estimated brain volume was extensively used as the in vivo proxy for neurodegeneration. 2 More recently, it has become a key outcome measure in the search for new efficacious therapies, 3 and it is now steadily moving towards its implementation in clinical practice for routine monitoring of disease evolution and treatment response in individual patients. 4 Absolute brain volume estimates were immediately substituted by parenchymal fractions, particularly for cross-sectional studies, as it was clear that the remaining brain was dependent on its initial maximal volume. 5 On the back of that, the concept of Brain Reserve stems from the notion that people with initially larger brains are more resistant to brain damage before any clinical signs of neurological impairment can be observed and has particularly been developed on the cognitive paradigm and measured using intracranial volume as a proxy of maximal lifetime brain growth. 6 However, do we need to take extra care of each patient brain reserve in our studies aiming at investigating the neurodegenerative component of multiple sclerosis? The answer is most probably no, as the brain volume outcomes in use do already take that into account in a way or another through adjusting by total intracranial volumes in the calculation of fractions or because they usually rely on percentage longitudinal changes. Moreover, brain reserve would only be relevant in cases where clinical correlations are to be considered and would not apply to any other studies on neurodegeneration, such as pathology studies. As it is fixed for any given individual and seems to be associated with the genetic background, it is highly likely that it is also not relevant for any within-subject approaches. A further consideration would be that research looking at specific areas or regions of the brain would be without a valid proxy, as the specific maximal lifetime growth of that structure could not be easily inferred. Finally, even though the concept has been well studied in Alzheimer's disease and seems to be incontrovertible, 7 the evidence in multiple sclerosis is still scarce and somewhat inconsistent; 8-10 differences in the pathophysiology of both diseases may underlie the differences observed.
In contrast to brain reserve, cognitive reserve relies on 'density' rather on simply 'volume' of the brain and relates to cognitive enrichment activities, usually in the premorbid stage. Some of the drawbacks already applied to the brain reserve concept can be argued against their use in all studies addressing neurodegeneration in multiple sclerosis, such as their sole relevance in research involving clinical outcomes. However, there are some aspects that clearly set cognitive reserve apart from brain reserve. As opposed to brain reserve, cognitive reserve is dynamic so that reserve-building activities are closely linked to rehabilitation interventions; 10 as a consequence, and interesting as this concept may be, its dynamic features transform cognitive reserve into a moving target which may be very difficult to reliably include as a covariate in neurodegeneration studies. And not just one but rather many moving targets as a large number of different proxies have been used to infer cognitive reserve in the studies performed to date in multiple sclerosis: verbal intelligence, cognitive leisure, education and a number of multifactorial indices including several of such proxies in a single score. 11 To add to the complexity, these different proxies have been associated with differential impacts on neuropsychological parameters, so that, for instance, education might have a protective effect against cognitive slowing 12 and cognitive leisure against memory impairment. 8 The interplay between cognitive and physical reserve and impairment on those domains adds a further layer of complexity. Overall, it may seem as taking brain and cognitive reserve always into account when studying neurodegeneration is not just an impossible mission but also one of unknown consequences.
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The author(s) received no financial support for the research, authorship and/or publication of this article. Cognitive dysfunction is highly prevalent, disabling, and poorly managed in persons with multiple sclerosis (PwMS). In these subjects, the presence and degree of cognitive dysfunction has been consistently associated with gray and white matter changes in the brain detected by magnetic resonance imaging (MRI) and especially with measures of whole brain and regional atrophy, currently interpreted as the best in vivo proxy for neurodegeneration. 1 However, not all PwMS present with cognitive dysfunction, even those having comparable degrees of gray and white matter changes and atrophy; moreover, longitudinal studies have shown great inter-subject variability in the rate of progression of cognitive dysfunction. 2 To explain this "clinicopathologic paradox," much attention has been drawn to other factors, namely the concept of reserve, that is, protection against clinical manifestations of neurological damage. Following extensive research in the field of degenerative dementia, there is now a growing body of evidence supporting brain reserve and, in particular, cognitive reserve also for mitigating the deleterious effects of MS pathology on cognition in PwMS. 3, 4 In his article, Sumowski highlights how consideration of reserve is of paramount importance to improve research on neurodegeneration, namely to help explain inter-individual differences in the cognitive outcome, inform the development of more accurate prognostic models of risk for cognitive dysfunction and the development of rehabilitative approaches based on reserve-building activities against ongoing neurodegeneration in the brain.
